Page last updated: 2024-11-13
fevipiprant
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
fevipiprant: a CRTh2 antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 23582412 |
| CHEMBL ID | 3137332 |
| SCHEMBL ID | 1940595 |
| MeSH ID | M000614493 |
Synonyms (48)
| Synonym |
|---|
| fevipiprant [jan] |
| fevipiprant [who-dd] |
| fevipiprant [usan] |
| nvp-qaw039 |
| qaw 039 |
| 1-(4-methanesulfonylbenzyl)-2-methyl-1h-pyrrolo(2,3-b)pyridin-3-yl)acetic acid |
| fevipiprant |
| 2-(1-((4-methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1h-pyrrolo(2,3-b)pyridin-3-yl)acetic acid |
| fevipiprant [usan:inn] |
| 2pex5n7dq4 , |
| unii-2pex5n7dq4 |
| fevipiprant [inn] |
| (1-(4-((methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1h-pyrrolo(2,3-b)pyridin-3-yl)acetic acid |
| 872365-14-5 |
| AB85348 |
| [2-methyl-1-[4-(methylsulfonyl)-2-(trifluoromethyl)benzyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]acetic acid |
| qaw039 |
| qaw-039 |
| CHEMBL3137332 |
| SCHEMBL1940595 |
| [1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid |
| fevipiprant (jan/usan/inn) |
| D10631 |
| AC-31956 |
| gtpl8995 |
| 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid |
| HY-16768 |
| AS-74870 |
| 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1h-pyrrolo[2,3-b]pyridin-3-yl)acetic acid |
| 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1h-pyrrolo[2,3-b]pyridin-3-yl)acetic acid |
| CS-5956 |
| mfcd22548206 |
| 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid |
| AKOS030629816 |
| DB12011 |
| (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1h-pyrrolo[2,3-b]pyridin-3-yl)acetic acid |
| BCP25015 |
| fevipiprant; nvp-qaw039; qaw039 |
| EX-A2495 |
| Q27077292 |
| bdbm50233520 |
| fevipiprant(nvp-qaw039) |
| FSY , |
| SB16897 |
| 2-methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1h-pyrrolo[2,3-b]pyridine-3-acetic acid |
| HMS3743E19 |
| FT-0774596 |
| DTXSID501336031 |
Research Excerpts
Overview
Fevipiprant is an oral, non-steroidal, highly selective, reversible antagonist of the prostaglandin D.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fevipiprant is an oral, non-steroidal, highly selective, reversible antagonist of the prostaglandin D" | ( The pharmacology of the prostaglandin D Altman, P; Brightling, C; Kulkarni, S; Lambrecht, BN; Sandham, D; Weiss, M, 2021) | 2.06 |
| "Fevipiprant (QAW039) is an oral treatment for asthma." | ( Fevipiprant in the treatment of asthma. Brightling, C; White, C; Wright, A, 2018) | 2.64 |
Toxicity
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The model was used to evaluate the intraluminal performance of the dosage forms and to predict the absorption rate limits for the 450 mg dose." | ( Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039. Dhareshwar, SS; Gajewska, M; Heimbach, T; Hirsch, S; Kourentas, A; Kulkarni, S; Lin, W; Mueller-Zsigmondy, M; Steib-Lauer, C, 2023) | 1.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "PK data from 1281 healthy subjects or asthma patients were available after single or once daily dosing of fevipiprant." | ( Bartels, C; Jain, M; Kulkarni, S; Sangana, R; Wang, X; Yu, J; Zack, J, 2021) | 0.83 |
| " The model was used to evaluate the intraluminal performance of the dosage forms and to predict the absorption rate limits for the 450 mg dose." | ( Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039. Dhareshwar, SS; Gajewska, M; Heimbach, T; Hirsch, S; Kourentas, A; Kulkarni, S; Lin, W; Mueller-Zsigmondy, M; Steib-Lauer, C, 2023) | 1.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (13)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7740 | 10.0000 | AID1433058 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7536 | 10.0000 | AID1433061 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.0151 | 10.0000 | AID1433060 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.8005 | 10.0000 | AID1433059 |
| Thromboxane A2 receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0011 | 0.7106 | 5.2000 | AID1433051 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0004 | 0.9585 | 8.0390 | AID1433049 |
| Prostaglandin F2-alpha receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0010 | 0.0106 | 0.0430 | AID1433050 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0009 | 0.1212 | 0.6350 | AID1433053 |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0022 | 0.7205 | 4.1690 | AID1433048 |
| Prostacyclin receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0084 | 0.0704 | 0.2880 | AID1433055 |
| Prostaglandin D2 receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0001 | 1.1583 | 7.3000 | AID1433047 |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.0045 | 0.0004 | 0.1009 | 0.9600 | AID1340841; AID1433030; AID1433031; AID1433040; AID1433041; AID1433042 |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | Ki | 0.0040 | 0.0006 | 0.6735 | 8.0000 | AID1340840; AID1433029 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 10.0000 | 0.0002 | 0.1921 | 1.9953 | AID1433054 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | EC50 (µMol) | 10.0000 | 0.0025 | 2.5405 | 5.0000 | AID1433052 |
| Prostacyclin receptor | Homo sapiens (human) | EC50 (µMol) | 10.0000 | 0.0004 | 0.0545 | 0.3470 | AID1433054 |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | Kd | 0.0010 | 0.0010 | 0.0010 | 0.0010 | AID1433046 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (104)
Molecular Functions (42)
Ceullar Components (13)
Bioassays (33)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1433051 | Antagonist activity at TP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433050 | Antagonist activity at FP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433036 | Clearance in Wistar rat at 0.5 mg/kg, iv or 3 mg/kg, po by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433060 | Inhibition of human CYP2D6 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433048 | Antagonist activity at EP2 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433044 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as dissociation rate constant by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433054 | Agonist activity at IP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433057 | Toxicity in dog | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433031 | Antagonist activity at DP2 receptor in human whole assessed as inhibition of DK-PGD2-induced eosinophils shape change preincubated for 5 mins followed by DK-PGD2 addition measured after 5 mins by flow cytometry | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433062 | Activation of PXR (unknown origin) assessed as CYP3A4 induction | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433052 | Agonist activity at EP3 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433049 | Antagonist activity at EP4 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433037 | Volume of distribution at steady state in Wistar rat at 0.5 mg/kg, iv or 3 mg/kg, po by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433030 | Antagonist activity at DP2 receptor in human isolated eosinophils assessed as inhibition of DK-PGD2-induced shape change preincubated for 5 mins followed by DK-PGD2 addition measured after 5 mins by flow cytometry | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433034 | Fraction unbound in plasma of Sprague-Dawley rat DK-PGD2-induced pulmonary eosinophilia mechanistic model at 0.03 to 0.1 mg/kg, po by equilibrium dialysis method | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433047 | Antagonist activity at DP1 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433045 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as dissociation half life by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433038 | Half life in Wistar rat at 0.5 mg/kg, iv by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433046 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433040 | Antagonist activity at DP2 receptor in CD4-positive human TH2 cells assessed as inhibition of DK-PGD2-induced IL-5 production after 6 to 8 hrs | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433042 | Antagonist activity at DP2 receptor in CD4-positive human TH2 cells assessed as inhibition of PGD2-induced IL-4 production preincubated for 30 mins followed by PGD2 addition measured after 6 hrs | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433061 | Inhibition of human CYP3A4 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433032 | In vivo antagonist activity at DP2 receptor in Sprague-Dawley rat DK-PGD2-induced pulmonary eosinophilia mechanistic model assessed inhibition of eosinophilia in broncho alveolar lavage fluid at 0.03 to 0.1 mg/kg, po pretreated for 40 mins starting at 2 h | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433029 | Displacement of [3H]PGD2 from human DP2 receptor expressed in CHO cell membranes after 60 mins by scintillation proximity assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433058 | Inhibition of human CYP1A2 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433043 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as association rate constant by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433041 | Antagonist activity at DP2 receptor in CD4-positive human TH2 cells assessed as inhibition of DK-PGD2-induced IL-13 production after 6 to 8 hrs | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433055 | Antagonist activity at IP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433056 | Toxicity in rat | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433059 | Inhibition of human CYP2C9 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433039 | Oral bioavailability in Wistar rat at 3 mg/kg by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433053 | Antagonist activity at EP3 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5 | Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1346326 | Human DP2 receptor (Prostanoid receptors) | 2016 | Molecular pharmacology, May, Volume: 89, Issue:5 | Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (31)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (54.84) | 24.3611 |
| 2020's | 14 (45.16) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 37.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (27.27%) | 5.53% |
| Reviews | 6 (18.18%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (54.55%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||